6Schlueter M,James C,Dominguez A, et al. Practice patterns for antibiotic de-escalation in culture-negative healthcare-associated pneumonia [ J ]. Infection, 2010,38 ( 5 ) : 357-362.
7Trouillet JL, Vuagnat A, Combes A, et al. Pseudomonas aeruginosa venti- lator-associated pneumonia: compari- son of episodes due to piperacillin-re- sistant versus piperaeillin-susceptib|e organisms [ J ]. Clin Infect Dis, 2002, 34(8) :1047-1054.
8Hussein K, Raz-Pasteur A, Finkel- stein R, et aL Impact of earbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumonia [ J ]. J Hosp Infect, 2013,83(4) :307-313.
6Swift CG. Pharmacokinetics and prescribing in the elderly [J]. J Antimicrob Agent, 1994, 34 (Supl A): 25-32.
7Faulkner CM, Cox HL, Williamson JC. Unique aspects of antimicrobial use in older adults [J]. Clin Infect Dis, 2005, 40: 997-1004.
8Fish DN, Singletary TJ. Meropenem, a new carbapenem antibiotic [J]. Pharmacotherapy. 1997, 17 (4): 644-669.
9Peters DH, Friedel HA, Mc Tavish D. Azithromycin, a review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy [J]. Drugs. 1992, 44 (5): 750-799.
10Burkhardt O, Welte T. 10 year' s experience with the pneumococcal quinolone moxifloxacin [J]. Expert Rev Anti Infect Ther. 2009, 7 (6): 645-668.
